190728-25-7

Basic information

• Product Name: BenzenaMine, 4-[(6,7-diMethoxy-4-quinolinyl)oxy]-
• Synonyms: BenzenaMine, 4-[(6,7-diMethoxy-4-quinolinyl)oxy]-;[4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl]amine;4-[(6,7-Dimethoxyquinolin-4-yl)oxy]aniline;6,7-Dimethoxy-4-(4-aminophenoxy)quinoline;BenzeMine, 4-[(6,7-diMethoxy-4-quinolinyl)oxy]-;4-[(6,7-diMethoxy-4-quinolinyl)oxy]-BenzenaMine;4-(2,3-dimethoxynaphthalen-5-yloxy)benzenamine;Intermediate 1 of Cabozantinib
• CAS NO: 190728-25-7
• Molecular Formula: C₁₇H₁₆N₂O₃
• Molecular Weight: 296.32054
• EINECS: -0
• Mol File: 190728-25-7.mol

Chemical Properties

• Melting Point: 211.0 to 215.0 °C
• Boiling Point: 481.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.246±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 6.79±0.30(Predicted)
• CAS DataBase Reference: BenzenaMine, 4-[(6,7-diMethoxy-4-quinolinyl)oxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: BenzenaMine, 4-[(6,7-diMethoxy-4-quinolinyl)oxy]-(190728-25-7)
• EPA Substance Registry System: BenzenaMine, 4-[(6,7-diMethoxy-4-quinolinyl)oxy]-(190728-25-7)

Safety Data

• Hazardous Substances Data: 190728-25-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Benzenamine, 4-[(6,7-dimethoxy-4-quinolinyl)oxy]is used as an intermediate in the synthesis of Cabozantinib Defluorination impurity. Cabozantinib is a tyrosine kinase inhibitor that is used to treat certain types of cancer, such as metastatic medullary thyroid cancer and renal cell carcinoma. The compound plays a crucial role in the preparation of this impurity, which is essential for the development and manufacturing of Cabozantinib.

Upstream product

• 190728-24-6 6,7?dimethoxy?4?(4?nitrophenoxy)quinoline 
• 4101-32-0 4',5'-dimethoxy-2'-nitroacetophenone 
• 1131-62-0 1-(3,4-dimethoxyphenyl)ethanone 
• 498-02-2 1-(3-methoxy-4-hydroxyphenyl)ethanone 
• 100-02-7 4-nitro-phenol 
• 350-46-9 4-Fluoronitrobenzene 
• 213699-53-7 5-(((3,4-dimethoxyphenyl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 35654-56-9 6,7-dimethoxy-4-chloroquinoline 
• 123-30-8 4-amino-phenol 
• 14593-46-5 sodium tert-pentoxide 
• 13425-93-9 6,7-dimethoxyquinoline-4-ol 
• 4101-30-8 2-amino-4,5-dimethoxyacetophenone 
• 26893-22-1 1,4-Dihydro-6,7-dimethoxy-4-oxo-3-quinolinecarboxylic acid 
• 127285-54-5 1,4-dihydro-6,7-dimethoxy-4-oxoquinoline 

Downstream Products

• 190727-14-1 N-{4-[(6,7-Dimethoxy-4-quinolyl)oxy]phenyl}-N'-(3-nitrophenyl)urea 

Relevant articles and documents

Crystal structures of intermediates in a new synthesis of antitumor drug cabozantinib

The heterocyclic antitumor drug cabozantinib was synthesized by condensation of 4-(6,7-dimethoxyquinolin-4-yloxy)aniline and methyl 1-(4-fluorophenylcarbamoyl)cyclopropanecarboxylate in the presence of two equivalents of sodium methoxide and azeotropic re

Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors

While the treatment of gastrointestinal stromal tumors (GISTs) has been revolutionized by the application of targeted tyrosine kinase inhibitors capable of inhibiting KIT-driven proliferation, diverse mutations to this kinase drive resistance to establish

Synthesis method of cabozantinib and intermediate thereof

The invention provides a synthesis method of cabozantinib and an intermediate thereof, and belongs to the field of medicinal chemistry. According to the invention, cyclopropane-1,1-dicarboxylic acid amine is used as a key intermediate, and reacts with sub

Preparation method of cabozantinib or salt thereof

The invention relates to a preparation method of cabozantinib or a salt thereof, which comprises the following steps: taking a compound shown as a formula I and 1-((4-fluorophenyl)carbamoyl)cyclopropanecarboxylic acid as raw materials, conducting reacting

PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF

Disclosed are a kinase inhibitor and a pharmaceutical composition comprising the kinase inhibitor. The kinase inhibitor comprises a compound as represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug

PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE

The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of protein kinases, and methods for their use in treating disorders mediated, at least in part by, protein kinases.

COMPOUNDS AND METHODS OF USE

The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of protein kinases, and methods for their use in treating disorders mediated, at least in part by, protein kinases.

Novel substituted pyrazolo [1, 5-a] pyrimidine compound and preparation method and application thereof

The invention provides a novel substituted pyrazolo [1, 5-a]pyrimidine compound and a preparation method and application thereof, and particularly relates to a pyrazolo [1, 5-a]pyrimidine-containing quinoline derivative shown as a general formula (I) and pharmaceutically acceptable salts thereof, and substituent groups X, Ar and A have meanings given in the specification. The invention also relates to a compound represented by the general formula (I), wherein the compound has a strong c-Met kinase inhibition effect. The invention also relates to application of the compound and the pharmaceutically acceptable salt thereof in preparation of drugs for treating and/or preventing diseases caused by abnormal high expression of c-Met kinase, especially application in preparation of drugs for treating and/or preventing cancers.

COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS

The present invention relates to compounds that modulate cellular activities such as proliferation, differentiation, programmed cell death, migration, and chemoinvasion, by modulating protein kinase enzymatic activity, and compositions thereof, and methods of using such compounds.

Preparation method of cabozantinib defluorination impurity

The invention discloses a preparation method of a cabozantinib defluorination impurity. The method comprises the following steps: preparing an intermediate 1, preparing 4-chloro-6, 7-dimethoxyquinoline, preparing an intermediate 2, and removing fluorine i